Why the study?
Does nafamostat mesilate improve vascular relaxation and cell protection compared to papaverine in conduits for coronary artery bypass surgery?
Does nafamostat mesilate improve vascular relaxation and cell protection compared to papaverine in conduits for coronary artery bypass surgery?
Nafamostat mesilate demonstrates potential as a superior conduit preserving agent compared to papaverine for coronary artery bypass surgery.
Hypothesis-generating for nafamostat in CABG conduits; human trials needed before clinical use.
NM exhibited good vascular relaxation and a reasonable anti-vasocontraction effect with a better cell protecting effect than papaverine; therefore, we concluded that NM is a good potential conduit preserving agent.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: